Business
Gain Therapeutics, Inc. Announces Appointment of Five Members to its Newly Formed Scientific Advisory Board (SAB)
Dr. Luca Benatti to Chair SAB BETHESDA, Md., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “company”), a
About this update from Gain Therapeutics, Inc.
[{"type":"text","content":"Dr. Luca Benatti to Chair SAB\nBETHESDA, Md., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced the formation of its Scientific Advisory Board (SAB). Luca Benatti, Ph.D. will serve as chair of the SAB. Additional appointments include Samuel Broder, M.D.; Lorenzo Leoni, Ph.D.; Joanne Taylor, Ph.D.; and Michel Vellard, Ph.D. “I am honored to welcome Dr. Benatti, Dr. Broder, Dr. Leoni, Dr. Taylor and Dr. Vellard to our advisory board and want to express my gratitude for their scientific contributions as we continue to expand our pipeline and progress Gain Therapeutics’ lead program in Parkinson’s Disease toward clinical studies,” said Eric Richman, Chief Executive Officer of Gain. “These individuals are luminaries in their respective fields and will perform significant roles in shaping our future clinical programs. And I would like to especially thank Dr. Benatti for his commitment to serve as chair of our SAB.” Luca Benatti, Ph.D., Chair of the Scientific Advisory BoardDr. Benatti will lead Gain’s SAB and work closely with the company’s leadership team to shape the scientific strategy and advance Gain’s early-stage programs. He has over 30 years of experience in the pharmaceutical and biotechnology industries. Dr. Benatti serves as the Chief Executive Officer and a Director of EryDel S.p.A., a private biotechnology company focused on rare diseases. Prior to EryDel, Dr. Benatti was Co-founder and CEO of Newron Pharmaceuticals S.p.A. Under his leadership, Newron developed a pipeline of innovative therapies including Xadago, approved worldwide for the treatment of Parkinson's Disease. Previously, Dr. Benatti held research and development positions at Pharmacia & Upjohn and its predecessor companies. Dr. Benatti has authored several scientific publications and holds a number of patents. He currently serves as a director of Intercept Pharmaceuticals, Newron Pharmaceuticals S.p.A. and Metis Precision Medicine. Dr. Benatti also serves as chairman of Italian Angels for Biotech, a member of the Advisory Board of the Sofinnova Telethon Fund, and as a member of the Development and of the Strategic Advisory ...